News – Page 1164 – Endpoints News

Tobira chairman’s dinner with Brent: Industry chat led to a 3-month pursuit and a stunning $1.7B deal

9 years ago

Soriot’s $3.5B Brilinta dream is dashed by yet another big trial flop for AstraZeneca

9 years ago

Summit shares rocket up, fueled by an $842M pact with Duchenne leader Sarepta

9 years ago

Korean officials launch Hanmi probe in wake of tox reports; Prothena CEO Schenk dies

9 years ago

Sun Pharma takes aim at a crowded market with another IL-23 psoriasis drug from Merck

9 years ago

Merrimack CEO is out as the biotech restructures, chopping its workforce and overhauling R&D

9 years ago

$95M mega-round in hand, Elaine Sullivan sets out to build a European oncology player

9 years ago

AstraZeneca hands off another Amgen-partnered drug in a $1.5B deal with an acquisitive Allergan

9 years ago

Presto! Wall Street magician Vivek Ramaswamy has another instant biotech IPO to sell you

9 years ago

J&J’s IL-23 star guselkumab grabs the spotlight in PhIII psoriasis showdown

9 years ago

Blockbuster performance: Regeneron, Sanofi add stellar PhIII dupilumab data on display at EADV

9 years ago

Following lethal tox report, Boehringer scraps plans for high-speed development, kills $730M Hanmi deal

9 years ago

Threshold blasted, restructures after a PhII failure; SQZ raises $16M

9 years ago

Week in review: Clinton over Trump; the hubs have it; we'll always have Paris

9 years ago

Scoop: Celgene targets a cure for myeloma/lymphoma with $600M EngMab buyout

9 years ago

In a setback, Regeneron reports a mid-stage flop for next-gen Eylea combo

9 years ago

ImmunoGen's new CEO retrenches, axing 65 staffers and looking to thin pipeline

9 years ago

UCSF scientist rolls out a new blueprint for programming T cells, the 2.0 way

9 years ago

Catabasis shares rocket up on Duchenne pact with Sarepta; bluebird whistles up a TCR deal with Medigene

9 years ago

Amgen beefs up cardio pipeline, adding a $673M RNAi deal with Arrowhead

9 years ago

Step two: Celgene grabs a $20M option, plots MS PhII for Abide’s cannabinoid drug

9 years ago

Novo Nordisk takes out the ax and aims at R&D, chopping 1,000 jobs

9 years ago

Genentech snares a PhI RAF inhibitor from Hanmi in $910M deal

9 years ago

FDA slaps a full clinical hold on Alcobra’s troubled lead drug for ADHD, Fragile X

9 years ago

First page Previous page 1161 1162 116311641165 1166 1167 Next page Last page